Next Article in Journal / Special Issue
ALK in Neuroblastoma: Biological and Therapeutic Implications
Previous Article in Journal
Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture
Previous Article in Special Issue
The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)
Open AccessReview

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma

Department of Pediatric Hematology and Oncology, Justus-Liebig University, D-35392 Giessen, Germany
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(4), 114; https://doi.org/10.3390/cancers10040114
Received: 28 February 2018 / Revised: 5 April 2018 / Accepted: 7 April 2018 / Published: 10 April 2018
Patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) mount a humoral and cellular immune response against ALK. More than 90% of children and adolescents with ALK-positive ALCL have detectable anti-ALK antibodies in serum or plasma, and the antibody titer inversely correlates with the risk of relapse. ALK-specific CD8 and CD4 T cell responses have been described in patients with ALK-positive ALCL. Vaccination with ALK DNA led to protection against lymphoma growth in a murine model. Collectively, these data suggest that the ALK-specific immune response is involved in the control of the disease. The characteristics of the humoral and cellular immune response against ALK as well as tumor immune escape mechanisms have been increasingly investigated. However, tumor and host factors contributing to the individual immune response against ALK are still largely unknown. Depending on the individual strength of the immune response and its determinants, individualized immunological approaches might be appropriate for the consolidation of ALCL patients. Strategies such as ALK vaccination could be effective for those with a pre-existing anti-tumor immunity, while an allogeneic blood stem cell transplantation or check-point inhibition could be effective for others. View Full-Text
Keywords: anaplastic large cell lymphoma; ALK; ALK-positive ALCL; immune response; ALK-specific T cells; ALK autoantibodies anaplastic large cell lymphoma; ALK; ALK-positive ALCL; immune response; ALK-specific T cells; ALK autoantibodies
Show Figures

Figure 1

MDPI and ACS Style

Stadler, S.; Singh, V.K.; Knörr, F.; Damm-Welk, C.; Woessmann, W. Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma. Cancers 2018, 10, 114.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop